(Press-News.org) NEW YORK, NY (May 16, 2021)--Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
In a clinical trial of the procedure, called renal denervation, daytime blood pressure after two months had dropped 8 points compared to a 3-point drop in patients who were treated with a sham procedure. Nighttime blood pressure decreased by an average of 8.3 points in the treatment group versus 1.8 points in the sham group.
"For patients with drug-resistant hypertension, a drop in blood pressure of 8 points--if maintained over longer-term follow-up--is almost certainly going to help reduce the risk of heart attack, stroke, and other adverse cardiac events," says Ajay Kirtane, MD, professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, an interventional cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center, and co-principal investigator of the trial.
"These results suggest that renal denervation has potential to become an important add-on to medication therapy--including for those who have difficulty managing several medications to control their hypertension."
Data from the trial, called RADIANCE-HTN TRIO, were presented May 16 at the American College of Cardiology conference and simultaneously published in The Lancet.
The treatment is still experimental, has not been approved for use by the FDA, and is only available through clinical trials. The trial will follow patients for five years to determine if the drop in blood pressure is maintained over time.
Need for Additional Blood Pressure-Lowering Therapies
About two-thirds of people who take medications to lower blood pressure are able to control their condition. But in others, the drugs do not work or people do not take them as directed.
"There are a variety of effective medications for lowering blood pressure, but many people need to take several drugs to control their hypertension, which can have side effects. In addition, many people simply don't want to take additional medications and are poorly adherent to them," says Kirtane. "It's clear that we need additional therapeutic approaches to help patients get their blood pressure under control."
Why Renal Denervation?
The kidney plays a role in blood pressure by controlling how much water is in the bloodstream (more water = more pressure) and acting as a central signaling center for other systems that regulate blood pressure. Renal denervation, a minimally invasive procedure, uses ultrasound energy to disrupt signals from overactive nerves in the renal arteries. The therapy is delivered via a catheter that is threaded through an artery in the leg.
Targeting these nerves is not a new idea in hypertension treatment; several existing medications reduce renal nerve activity to reduce blood pressure.
"But unlike medications, which are only effective when you take them, renal denervation is a therapy that's always 'on,'" Kirtane says.
Initial studies of renal denervation had several flaws--including the lack of an adequate control group, variable measurement of participants' blood pressure, and frequent changes in background medications--that made the results challenging to interpret.
How the Study Worked
In this study, the researchers tested the effectiveness and safety of a device that delivers two to three short blasts of ultrasound to nerve fibers that travel close to the renal artery.
The study included adults with moderate to severe hypertension despite taking three or more antihypertensive drugs. All of the patients were switched to the same medication regimen for their hypertension. (To help with patient adherence, participants took a single pill that combined three commonly used antihypertensive drugs.)
"In our study, 80% of patients continued to take their medication as directed, and while that's a good adherence rate, it still means that one in five patients weren't adherent to the medication regimen," Kirtane adds.
Of 136 patients whose blood pressure remained high after four weeks on the new regimen, 69 were treated with renal denervation and 67 had the sham procedure.
Previous studies in patients with less severe hypertension who were not taking any antihypertensive medications showed that renal denervation was more effective than a sham procedure in lowering blood pressure.
"Additional studies will be needed to determine if this therapy may be effective for other groups, including older patients with hypertension and those with chronic kidney disease," says Kirtane.
INFORMATION:
More Information
The study, titled "Ultrasound renal denervation for hypertension resistant to triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial," was published online in The Lancet on May 16, 2021.
Michel Azizi (Université de Paris, France) and Ajay J. Kirtane (Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian), co-corresponding authors, contributed equally to the manuscript. Additional authors are listed in the article.
The study was funded by ReCor Medical, Inc., the manufacturer of the Paradise Renal Denervation System.
Disclosures: Dr. Kirtane reports institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Neurotronic. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting/speaking engagements. Personal: travel expenses/meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cuimc.columbia.edu or columbiadoctors.org.
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Clinical Cancer Research, has found a combination of therapies that appears to be highly effective against high-risk neuroblastoma and other forms of aggressive childhood cancer.
Up to half of all cases of neuroblastoma newly diagnosed in children are 'high-risk', meaning the cancer grows aggressively and is difficult to treat. Despite receiving intensive treatment, most children with high-risk disease die within five years of diagnosis, while those who survive are often left with serious ...
ATS 2021, New York, NY - A weighted "lottery" designed to increase access to the antiviral drug remdesivir during the May-July 2020 COVID-19 surge for those most affected by the coronavirus, including members of the Black, Latinx and indigenous communities, led to more equitable distribution of the badly needed medication, according to research presented at the ATS 2021 International Conference.
At a time when supplies of COVID-19 medications were scarce, Douglas B. White, MD, MAS, vice chair and professor of critical care medicine, UPMC endowed chair for ethics in critical care medicine and director of the Program on Ethics and Decision Making in Critical Illness, University of Pittsburgh School of Medicine, and colleagues, convened ...
WINSTON-SALEM, N.C. - May 16, 2021 - Heart failure (HF) - when the heart can't pump enough blood and oxygen through the body - affects approximately 6.2 million adults in the United States and is the primary cause of hospitalization in the elderly. Unfortunately, older adults with heart failure often have poor outcomes resulting in reduced quality of life, high mortality and frequent rehospitalizations.
Despite many efforts to improve the prognosis in these patients, most previous studies testing a wide range of interventions were not successful.
Scientists from the Wake Forest, Duke University and Thomas Jefferson ...
An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs. Supported by the National Institute on Aging (NIA), part of the National institutes of Health, these new study results were published May 16 in the New England Journal of Medicine and also presented at the American College of Cardiology's 70th Annual Scientific Session.
"Designing earlier and more personalized individual-specific approaches to heart failure rehab shows great promise for improving outcomes for this common but complex condition that is ...
The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai. The fully human monoclonal antibody produced sustained reductions in triglyceride levels of up to 82 percent, depending on the patient's genotype, while also lowering the risk of recurrent acute pancreatitis. The results of the study will be presented as a late-breaking clinical trial at the American College of Cardiology (ACC) Annual Scientific Session, on May 16.
"Evinacumab has the potential to not only lower triglycerides, but the risk of acute pancreatitis, quality of life, and the risk of cardiovascular events in ...
Hamilton, ON (May 15, 2021) - A simple surgery saves patients with heart arrhythmia from often-lethal strokes, says a large international study led by McMaster University.
Researchers found that removing the left atrial appendage -- an unused, finger-like tissue that can trap blood in the heart chamber and increase the risk of clots -- cuts the risk of strokes by more than one-third in patients with atrial fibrillation.
Even better, the reduced clotting risk comes on top of any other benefits conferred by blood-thinner medications patients with this condition are usually prescribed.
"If you have atrial fibrillation and are undergoing heart surgery, the surgeon should be removing your left atrial appendage, because it is a set-up for forming clots. Our trial has shown ...
Researchers at Rutgers Robert Wood Johnson Medical School are reporting the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in people's arms.
The discovery, published in the journal Viruses, improves the understanding of how inflammation caused by COVID-19 can lead to upper extremity blood clots and how best to treat them. The case study is part of a larger Rutgers study of 1,000 hospitalized patients diagnosed with COVID-19 who were admitted and discharged between March and May 2020.
While there have been reports of lower extremity deep vein thrombosis following COVID-19, ...
Next-generation sequencing technology has made it easier than ever for quick diagnosis of plant diseases. "It's really exciting to see how sequencing technologies have evolved and how this new technology facilitates sequencing of entire genomes in such a short amount of time," said Yazmín Rivera, a plant pathologist with the United States Department of Agriculture's Plant Protection and Quarantine program, who recently published a research paper on the efficacy of Oxford Nanopore Technologies protocols.
"We wanted to provide an unbiased assessment of the technology and protocols available for long read sequencing," Rivera explained. Along with other plant pathologists, Rivera used the company's protocols to prepare RNA and DNA libraries from virus-infected plant material ...
People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.
Analyzing data from participants in the UK Biobank, the researchers estimated that maintaining a healthy lifestyle was associated with a nearly 40% reduction in colorectal cancer risk among those with a high genetic risk of developing the disease. The percentage dropped to only about 25% among people at ...
Dozens of commonly used drugs, including antibiotics, antinausea and anticancer medications, have a potential side effect of lengthening the electrical event that triggers contraction, creating an irregular heartbeat, or cardiac arrhythmia called acquired Long QT syndrome. While safe in their current dosages, some of these drugs may have a more therapeutic benefit at higher doses, but are limited by the risk of arrhythmia.
Through both computational and experimental validation, a multi-institutional team of researchers has identified a compound that prevents the lengthening of the heart's electrical event, or action potential, resulting in a major step toward safer use and expanded therapeutic efficacy of these ...
